Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:USA FDA Guidance for Industry - Electronic Source Data in Clinical Investigations Sep-2013 III 2.: Difference between revisions

From GxPlex

Jump to: navigation, search
Migrate to Template:ReferenceData for PageForms (GxPlexBot)
m 1 revision imported
 
(No difference)

Latest revision as of 13:50, 16 July 2026



Document information
Reference USA FDA Guidance for Industry -

Electronic Source Data in Clinical Investigations Sep-2013

Validity area USA
Scope(s) G
Document name FDA Guidance for Industry -

Electronic Source Data in Clinical Investigations

Version / Revision Sep-2013
Status Current
Document type Official recommendation
Language(s) EN
Description Guidance for Industry Electronic Source Data in Clinical Investigations
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 4 — Unit 4.2.2
Scope G
Document part III 2.
Language EN
Original entry by Florian Adragna
Contributors
Tags Electronic records, Source documents, Case report form, Electronic data capture, FDA

Content

III. Electronic Source Data [...] 2. Source Data Capture Data can be entered into the eCRF either manually or electronically as described below. a. Direct Entry of Data Into the eCRF Many data elements (e.g., blood pressure, weight, temperature, pill count, resolution of a symptom or sign) in a clinical investigation can be obtained at a study visit and can be entered directly into the eCRF by an authorized data originator. This direct entry of data can eliminate errors by not using a paper transcription step before entry into the eCRF. For these data elements, the eCRF is the source. If a paper transcription step is used, then the paper documentation should be retained and made available for FDA inspection (see section III.A.2.c). When pertinent supportive information is available, FDA could request other documents during an inspection to corroborate a direct entry of source data elements into the eCRF by an authorized data originator. For example, at an initial visit, a clinical investigator might ask a subject about underlying illnesses, and proceed to enter the illness(es) in an eCRF. During an FDA inspection, a record may be requested for evidence of testing or the use of medications to corroborate a diagnosis.